medigraphic.com

2023, Number 3

Next >>

Rev Hematol Mex 2023; 24 (3)

Clinical-demographic characterization and evaluation of prognostic markers in patients diagnosed with mantle cell lymphoma in a health institution in Colombia, 2018-2021

Adams PJM, Jiménez MAMP, Cuervo PJF, Lozano BDM

Language: Spanish
References: 53
Page: 113-127
PDF size: 325.60 Kb.


ABSTRACT

Objective: To describe the clinical-demographic and pathological characteristics with prognostic value in the diagnosis of patients with mantle cell lymphoma in a tertiary health service provider institution in Colombia.
Materials and Methods: A descriptive cross-sectional study was carried out where patients diagnosed with mantle cell lymphoma from 2018 to 2021 of a health institution were included. The information was collected from medical records and the statistical analysis was performed in SPSS version 25.0.
Results: There were included 50 patients. A higher incidence was found in men, with a mean age of 65 years, with lymph nodes being the most affected organs and the classic variant and mixed infiltration being the most prevalent. Among the most relevant findings, the statistical association between hemoglobin and MIPI stood out, showing that patients with anemia were more likely to belong to the high-risk group.
Conclusions: This study contributes with data on the incidence of this neoplasia in Colombia, identifying factors that affect its evolution and severity. In addition, it generates new hypotheses to continue in the search for prognostic markers that provide the clinician with a greater approach to the reality of each patient, allowing more personalized care.


REFERENCES

  1. Jaffe ES, Campo E, Harris NL, et al. Introduction and overviewof the classification of lymphoid neoplasms. WHOclassification of tumours of haematopoietic and lymphoidtissues. 4th ed. International Agency for Research on Cancer,Lyon France, 2017; 190-98.

  2. Mugnaini E, Ghosh N. Lymphoma. Prim Care 2016; 43 (4):661-73. doi: 10.1016/j.pop.2016.07.012.

  3. Centers for Disease Control and Prevention. United StatesCancer Statistics: Data Visualizations. 2019. https://gis.cdc.gov/Cancer/USCS/#/AtAGlance/.

  4. GLOBOCAN 2020. World Health Organization (WHO).https://gco.iarc.fr/today/.

  5. Fondo Colombiano de Enfermedades de Alto Costo.Situación del cáncer en la población adulta atendida enel SGSSS de Colombia 2021.Cuenta de Alto Costo. 2022.

  6. Swerdlow S, Campo E, Seto M, Muller-Hermelink HK.Mantle cell lymphoma. WHO classification of tumours ofhaematopoietic and lymphoid tissues. 4th ed. InternationalAgency for Research on Cancer, Lyon France, 2017; 285-90.

  7. Rule S, Johns S. Advances in classification and treatment ofnon-Hodgkin lymphoma: Mantle cell. Cancer J 2020; 26 (4):348-56. doi: 10.1097/PPO.0000000000000462.

  8. García Ramírez CA, Uribe Pérez CJ, Marina P, Vargas N,Sebastián D, Radi S, et al. Linfomas no Hodgkin: Áreametropolitana de Bucaramanga. Revista de la UniversidadIndustrial de Santander 2011; 43 (1): 39-47.

  9. Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL,Flowers CR. New insights into the epidemiology ofnon-Hodgkin lymphoma and implications for therapy.Expert Rev Anticancer Ther 2015; 15 (5): 531-44. doi:

  10. 10.1586/14737140.2015.1023712.10. Thandra K, Barsouk A, Saginala K, Padala S, Barsouk A, RawlaP. Epidemiology of Non-Hodgkin’s Lymphoma. Med Sci(Basel) 2021; 9 (1): 267-75. doi: 10.3390/medsci9010005.

  11. Smedby KE, Sampson JN, Turner JJ, Slager SL, Maynadié M,Roman E, et al. Medical history, lifestyle, family history, andoccupational risk factors for mantle cell lymphoma: TheInterLymph Non-Hodgkin Lymphoma Subtypes Project.J Natl Cancer Inst Monogr 2014; 2014 (48): 76-86. doi:10.1093/jncimonographs/lgu007.

  12. McKinney M and Dave S. Origins of non-Hodgkin lymphomas.In: Hoffman R, Benz E, Silberstein L, et al, editor.Hematology: Basic Principles and Practice. 7th ed. Philadelphia:Elsevier; 2018: 1230-243.

  13. Cortelazzo S, Ponzoni M, Ferreri AJM, Dreyling M. Mantlecell lymphoma. Crit Rev Oncol Hematol 2020; 153. doi:10.1016/j.critrevonc.2020.103038.

  14. Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, et al. Geneticmutations and features of mantle cell lymphoma: asystematic review and meta-analysis. Blood Adv 2020; 4(13): 2927-38. doi:10.1182/bloodadvances.2019001350.

  15. Silkenstedt E, Linton K, Dreyling M. Mantle cell lymphoma– advances in molecular biology, prognostication and treatmentapproaches. Br J Haematol 2021; 195 (2): 162-73.doi: 10.1111/bjh.17419.

  16. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD,Araujo IB de O, Berti E, et al. The 5th edition of the WorldHealth Organization Classification of HaematolymphoidTumours: Lymphoid Neoplasms. Leukemia. Springer Nature;2022; 36: 1720-48.

  17. Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H,Siebert R, et al. The 2016 revision of the World Health Organizationclassification of lymphoid neoplasms. Blood 2016;127 (20): 2375. doi.org/10.1182/blood-2016-01-643569.

  18. Pinilla M and Moreno S. Neoplasia folicular in situ y neoplasiade células del manto in situ: incidencia y significadoclínico. Tesis doctoral. España. 2017.

  19. Lee W, Shin E, Kim BH, Kim H. Diagnostic accuracy ofSOX11 immunohistochemistry in mantle cell lymphoma:A meta-analysis. PLoS One 2019; 14 (11). doi: 10.1371/journal.pone.0225096.

  20. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, vanHoof A, Kluin-Nelemans HC, et al. A new prognostic index(MIPI) for patients with advanced-stage mantle celllymphoma. Blood 2008; 111 (2): 558-65. doi: 10.1182/blood-2007-06-095331.

  21. Acevedo C. Características clínico-patológicas y su implicanciaen la sobrevida de pacientes con linfoma de células delmanto. Instituto Nacional de Enfermedades Neoplásicas,2002-2012. 2015.

  22. Balagué O, Colomo L, Campo E. Linfoma de células delmanto. Patol 2004; 37: 159-72.

  23. Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, GutiérrezG, et al. Central nervous system involvement in mantle celllymphoma. Ann Oncol 2008; 19 (1): 135-41. doi: 10.1093/annonc/mdm447.

  24. Vose JM. Mantle cell lymphoma: 2017 update on diagnosis,risk-stratification, and clinical management. Am J Hematol2017; 92 (8): 806-13. doi: 10.1002/ajh.24797.

  25. Campo E and Jares P. Mantle Cell Lymphoma. In: Jaffe E,Arber E, Campo E, et al. editor. Hematopathology. 2nd ed.Philadelphia: Elsevier; 2017: 397-414.

  26. Schlüter C, Duchrow M, Wohlenberg C, Becker MH, et al.The cell proliferation-associated antigen of antibody Ki-67:a very large, ubiquitous nuclear protein with numerousrepeated elements, representing a new kind of cell cyclemaintainingproteins. J Cell Biol 1993; 123 (3): 513-522.doi:10.1083/jcb.123.3.513

  27. He X, Chen Z, Fu T, Jin X, Yu T, Liang Y, et al. Ki-67 is a valuableprognostic predictor of lymphoma but its utility variesin lymphoma subtypes: evidence from a systematic metaanalysis.BMC Cancer 2014; 14: 153. doi: 10.1186/1471-2407-14-153.

  28. Aqil B, Triska G, Frater J, Hassan A, Ruzinova MB, CashenA, et al. Immunophenotypic variations in mantle cell lymphomaand their impact on clinical behavior and outcome.Arch Pathol Lab Med 2018; 142 (10): 1268-74. doi: 10.5858/arpa.2017-0368-OA.

  29. Hu Z, Sun Y, Schlette EJ, Tang G, Li S, Xu J, et al. CD200expression in mantle cell lymphoma identifies a uniquesubgroup of patients with frequent IGHV mutations,absence of SOX11 expression, and an indolent clinicalcourse. Mod Pathol 2018; 31 (2): 327-36. doi: 10.1038/modpathol.2017.135.

  30. Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S,Loddenkemper C, et al. Prognostic value of Ki-67 index,cytology, and growth pattern in mantle-cell lymphoma:Results from randomized trials of the European Mantle CellLymphoma Network. J Clin Oncol 2016; 34 (12): 1386–94.doi: 10.1200/JCO.2015.63.8387.

  31. Pérez-Cruz PE, Acevedo F. Escalas de estado funcional (operformance status) en cáncer. Gastroenterol Latinoam2014; 25 (3): 219-26.

  32. Okay M, Meletli O, Kelkitli E, Malkan UY, Turgut M, BuyukasikY, et al. Mantle cell lymphoma: a Turkish Multi-CenterStudy. J BUON 2019; 24 (5): 2084-2089.

  33. Zhou P, Shi Y, He X, Zhou S, Liu P, Dong M, et al. [Clinicalfeatures and prognostic analysis of mantle cell lymphomapatients]. Zhonghua Zhong Liu Za Zhi 2014; 36 (12): 928-32.

  34. Enciso LJ, Suarez ML, Arango M. Resultados del tratamientodel linfoma de células del manto con varios regímenesde inmunoquimioterapia: estudio retrospectivo. RevistaColombiana de Cancerología. Instituto Nacional de CancerologíaESE; 2015; 19: 71-80.

  35. Jo JC, Kim SJ, Lee HS, Eom HS, Lee SI, Park Y, et al. Clinicalfeatures and treatment outcomes of limited-stage mantlecell lymphoma: Consortium for Improving Survival ofLymphoma report. Ann Hematol 2020; 99 (2): 223-228.doi: 10.1007/s00277-019-03803-x.

  36. He JS, Chen X, Wei GQ, Sun J, et al. Simplified MIPI-Bprognostic stratification method can predict the outcomewell-retrospective analysis of clinical characteristics andmanagement of newly-diagnosed mantle cell lymphomapatients from China. Medicine (Baltimore) 2019; 98 (1):e13741. doi:10.1097/MD.0000000000013741.

  37. Mehmet Ali U, Simten D, Murat A, Osman S, Funda C,Mesude F, et al. Prognostic significance of MIPI andMIPI-B scoring systems for mantle cell lymphoma in theTurkish population. Clin Hematol Res 2019; 2 (1). doi:10.36959/831/379.

  38. Rojas G. Descripción clínico patológica y expresión del inmunomarcadorSOX11 en pacientes con linfoma del manto.Universidad Nacional de Colombia. 2012.

  39. Caballero D, Campo E, López-Guillermo A, Martín A,Arranz-Sáez R, Giné E, et al. Clinical practice guidelinesfor diagnosis, treatment, and follow-up of patients withmantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. Ann Hematol 2013; 92(9): 1151-79. doi: 10.1007/s00277-013-1783-4.

  40. Tiemann M, Schrader C, Klapper W, Dreyling MH, CampoE, Norton A, et al. Histopathology, cell proliferation indicesand clinical outcome in 304 patients with mantle celllymphoma (MCL): a clinicopathological study from theEuropean MCL Network. Br J Haematol 2005; 131: 29-38.doi: 10.1111/j.1365-2141.2005.05716.x.

  41. Vogt N, Klapper W. Variability in morphology and cell proliferationin sequential biopsies of mantle cell lymphoma atdiagnosis and relapse: clinical correlation and insights intodisease progression. Histopathology 2013; 62 (2): 334-42.doi: 10.1111/his.12009. PMID: 23240716.

  42. Jain P, Zhang S, Shamanna R, Ok CY, Nomie K, GonzalezGN, et al. Genomic profiles and clinical outcomes of denovo blastoid/pleomorphic MCL are distinct from thoseof transformed MCL. Blood Adv 2020; 4 (6): 1038-1050.doi: 10.1182/bloodadvances.

  43. Cheah CY, George A, Giné E, Chiappella A, Nelemans HC, JurczakW, et al. Central nervous system involvement in mantlecell lymphoma: clinical features, prognostic factors and outcomesfrom the European Mantle Cell Lymphoma Network.Ann Oncol 2013; 8: 2119-23. doi: 10.1093/annonc/mdt139.

  44. Yoo C, Yoon DH, Kim S, Huh J, Park CS, Park CJ, et al. Serumbeta-2 microglobulin as a prognostic biomarker in patientswith mantle cell lymphoma. Hematol Oncol 2016; 34 (1):22-7. doi: 10.1002/hon.2188.

  45. Dreyling M, Hoster E, Unterhalt M, Rosenwald A, Kluin-Nelemans H, Hermine O, et al. Clinical outcome of mantlecell lymphoma patients with high risk biology (high Ki-67,blastic MCL, or high p53 expression). Blood 2019; 134 (1):3996. doi:org/10.1182/blood-2019-130068.

  46. Silkenstedt E, Linton K, Dreyling M. Mantle cell lymphoma- advances in molecular biology, prognostication and treatmentapproaches. Br J Haematol 2021; 195 (2): 162-173.doi: 10.1111/bjh.17419.

  47. Campo E, Jaffe E, Cook J, Quintanilla L, Swerdlow S, AndersonK, et al. The International Consensus Classification ofMature Lymphoid Neoplasms: A report from the ClinicalAdvisory Committee. Blood 2022; 140 (11): 1229-1253.doi/10.1182/blood.2022015851.

  48. Mishra P, Padhi S, Ayyanar P, Samal S, Majumdar S,Panigrahi A, et al. Clinicopathological and immunohistochemicalprofile of mantle cell lymphoma: An institutionalexperience. Cureus 2021; 13 (7): e16534. doi: 10.7759/cureus.16534.

  49. Garcia M, Navarro A, Mas R, Clot G, Abril J, PrietoM, et al. CCND2 and CCND3 hijack immunoglobulinlight-chain enhancers in cyclin D1- mantle cell lymphoma.Blood 2019; 133 (9): 940-951. doi: 10.1182/blood-2018-07-862151.

  50. Miao Y, Lin P, Saksena A, Xu J, Wang M, RomagueraJ, et al. CD5-negative mantle cell lymphoma: Clinicopathologiccorrelations and outcome in 58 patients. AmJ Surg Pathol 2019; 43 (8): 1052-1060. doi: 10.1097/PAS.0000000000001278.

  51. Akhter A, Mahe E, Street L, Pournazari P, Perizzolo M, Rad M,et al. CD10-positive mantle cell lymphoma: biologically distinctentity or an aberrant immunophenotype? Insight, throughgene expression profile in a unique case series. J Clin Pathol2015; 68 (10): 844-8. doi: 10.1136/jclinpath-2015-202955.

  52. Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-LarueMH, Rymkiewicz G, et al. Expression of TP53 is associatedwith the outcome of MCL independent of MIPI and Ki-67in trials of the European MCL Network. Blood 2018; 131(4): 417-20. doi: 10.1182/blood-2017-07-797019.

  53. Hu MW, Lou YJ, Yang M, Wang HF, Wang L, Jin J. [Clinicalanalysis of 140 cases of mantle cell lymphoma]. ZhonghuaZhong Liu Za Zhi 2018; 40 (5): 390-395. doi: 10.3760/cma.j.issn.0253-3766.2018.05.013.




2020     |     www.medigraphic.com